cyc 682 has been researched along with Myelodysplastic Syndromes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boone, PA; Chiao, JH; Cortes, J; Faderl, S; Garcia-Manero, G; Green, SR; Kantarjian, H; O'Brien, S; Plunkett, W; Ravandi, F; Westwood, R | 1 |
| Jabbour, E; Kadia, TM; Kantarjian, H | 1 |
1 review(s) available for cyc 682 and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Drug Resistance; Drug Substitution; Enzyme Inhibitors; Glutathione; Glycine; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation; Sulfones; Treatment Failure | 2011 |
1 trial(s) available for cyc 682 and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cytosine; Drug Administration Schedule; Humans; Leukemia; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Survival Analysis | 2010 |